Please assess the completion status of the following clinical trial:

Trial Title: Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI≥30 kg/m2.~* Conventional diagnosis of atherogenic dyslipidemia, confirmed by a fasting serum TG more than150 mg/dl coincide with an HDL-C of less than 50 mg/dl.~Exclusion Criteria:~* The use of any antilipidemic medication.~* Findings suggestive for renal dysfunction (eGFR˂60ml/min per 1.73 m2).~* Findings suggestive for hepatic insufficiency (ALT and/or AST˃2ULN).~* Clinical or laboratory findings suggestive for thyroid dysfunction.~* Established diagnosis of Diabetes Mellitus.~* History of gout, hyperuricemia, or on hypouricemic agents.~* Active peptic ulcer.~* Pregnancy, or nursing mothers.~* Alcohol or tobacco consumption.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
- Fenofibrate Monotherapy (Type: ACTIVE_COMPARATOR): Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
- WMER Niacin Monotherapy (Type: ACTIVE_COMPARATOR): Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
- Combination Therapy (Type: ACTIVE_COMPARATOR): Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).